Table 2.
Baseline characteristics of HCC patients in different risk groups.
| TCGA cohort | ICGC cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Cases | High risk n (%) | Low risk n (%) | P value | Cases | High risk n (%) | Low risk n (%) | P value |
| Gender | 365 | 231 | ||||||
| Male | 246 | 128 (52.0) | 118 (48.0) | 170 | 88 (51.8) | 82 (48.2) | ||
| Female | 119 | 54 (45.4) | 65 (54.6) | 0.233 | 61 | 27 (44.3) | 34 (55.7) | 0.315 |
| Age (years) | 365 | 231 | ||||||
| >65 | 138 | 68 (49.3) | 70 (50.7) | 142 | 72 (50.7) | 70 (49.3) | ||
| ≤65 | 227 | 114 (50.2) | 113 (49.8) | 0.816 | 89 | 43 (48.3) | 46 (51.7) | 0.724 |
| Grade | 360 | — | ||||||
| G1+G2 | 230 | 96 (41.7) | 134 (58.3) | — | — | — | ||
| G3+G4 | 130 | 84 (64.6) | 46 (35.4) | <0.001 | — | — | — | — |
| Invasive extent | 362 | — | ||||||
| T1-2 | 271 | 129 (47.6) | 142 (52.4) | — | — | — | ||
| T3-4 | 91 | 53 (58.2) | 38 (41.8) | 0.079 | — | — | — | — |
| TNM stage | 341 | 231 | ||||||
| I+II | 254 | 119 (46.9) | 135 (53.1) | 141 | 60 (42.6) | 81 (57.4) | ||
| III+IV | 87 | 50 (57.5) | 37 (42.5) | 0.087 | 90 | 55 (61.1) | 35 (38.9) | 0.006 |
HCC: hepatocellular carcinoma; ICGC: International Cancer Genome Consortium; TCGA: The Cancer Genome Atlas.